A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer
Abstract The association between genetic variations and immunotherapy benefit has been widely recognized, while such evidence in gastrointestinal cancer remains limited. We analyzed the genomic profile of 227 immunotherapeutic gastrointestinal cancer patients treated with immunotherapy, from the Mem...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/af919b7c4d764432868744aa0e66f40a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:af919b7c4d764432868744aa0e66f40a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:af919b7c4d764432868744aa0e66f40a2021-12-02T14:41:51ZA genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer10.1038/s41698-021-00172-52397-768Xhttps://doaj.org/article/af919b7c4d764432868744aa0e66f40a2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41698-021-00172-5https://doaj.org/toc/2397-768XAbstract The association between genetic variations and immunotherapy benefit has been widely recognized, while such evidence in gastrointestinal cancer remains limited. We analyzed the genomic profile of 227 immunotherapeutic gastrointestinal cancer patients treated with immunotherapy, from the Memorial Sloan Kettering (MSK) Cancer Center cohort. A gastrointestinal immune prognostic signature (GIPS) was constructed using LASSO Cox regression. Based on this signature, patients were classified into two subgroups with distinctive prognoses (p < 0.001). The prognostic value of the GIPS was consistently validated in the Janjigian and Pender cohort (N = 54) and Peking University Cancer Hospital cohort (N = 92). Multivariate analysis revealed that the GIPS was an independent prognostic biomarker. Notably, the GIPS-high tumor was indicative of a T-cell-inflamed phenotype and immune activation. The findings demonstrated that GIPS was a powerful predictor of immunotherapeutic survival in gastrointestinal cancer and may serve as a potential biomarker guiding immunotherapy treatment decisions.Xi JiaoXin WeiShuang LiChang LiuHuan ChenJifang GongJian LiXiaotian ZhangXicheng WangZhi PengChangsong QiZhenghang WangYujiao WangYanni WangNa ZhuoHenghui ZhangZhihao LuLin ShenNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Precision Oncology, Vol 5, Iss 1, Pp 1-9 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Xi Jiao Xin Wei Shuang Li Chang Liu Huan Chen Jifang Gong Jian Li Xiaotian Zhang Xicheng Wang Zhi Peng Changsong Qi Zhenghang Wang Yujiao Wang Yanni Wang Na Zhuo Henghui Zhang Zhihao Lu Lin Shen A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer |
| description |
Abstract The association between genetic variations and immunotherapy benefit has been widely recognized, while such evidence in gastrointestinal cancer remains limited. We analyzed the genomic profile of 227 immunotherapeutic gastrointestinal cancer patients treated with immunotherapy, from the Memorial Sloan Kettering (MSK) Cancer Center cohort. A gastrointestinal immune prognostic signature (GIPS) was constructed using LASSO Cox regression. Based on this signature, patients were classified into two subgroups with distinctive prognoses (p < 0.001). The prognostic value of the GIPS was consistently validated in the Janjigian and Pender cohort (N = 54) and Peking University Cancer Hospital cohort (N = 92). Multivariate analysis revealed that the GIPS was an independent prognostic biomarker. Notably, the GIPS-high tumor was indicative of a T-cell-inflamed phenotype and immune activation. The findings demonstrated that GIPS was a powerful predictor of immunotherapeutic survival in gastrointestinal cancer and may serve as a potential biomarker guiding immunotherapy treatment decisions. |
| format |
article |
| author |
Xi Jiao Xin Wei Shuang Li Chang Liu Huan Chen Jifang Gong Jian Li Xiaotian Zhang Xicheng Wang Zhi Peng Changsong Qi Zhenghang Wang Yujiao Wang Yanni Wang Na Zhuo Henghui Zhang Zhihao Lu Lin Shen |
| author_facet |
Xi Jiao Xin Wei Shuang Li Chang Liu Huan Chen Jifang Gong Jian Li Xiaotian Zhang Xicheng Wang Zhi Peng Changsong Qi Zhenghang Wang Yujiao Wang Yanni Wang Na Zhuo Henghui Zhang Zhihao Lu Lin Shen |
| author_sort |
Xi Jiao |
| title |
A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer |
| title_short |
A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer |
| title_full |
A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer |
| title_fullStr |
A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer |
| title_full_unstemmed |
A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer |
| title_sort |
genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/af919b7c4d764432868744aa0e66f40a |
| work_keys_str_mv |
AT xijiao agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT xinwei agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT shuangli agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT changliu agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT huanchen agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT jifanggong agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT jianli agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT xiaotianzhang agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT xichengwang agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT zhipeng agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT changsongqi agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT zhenghangwang agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT yujiaowang agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT yanniwang agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT nazhuo agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT henghuizhang agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT zhihaolu agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT linshen agenomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT xijiao genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT xinwei genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT shuangli genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT changliu genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT huanchen genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT jifanggong genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT jianli genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT xiaotianzhang genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT xichengwang genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT zhipeng genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT changsongqi genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT zhenghangwang genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT yujiaowang genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT yanniwang genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT nazhuo genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT henghuizhang genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT zhihaolu genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer AT linshen genomicmutationsignaturepredictstheclinicaloutcomesofimmunotherapyandcharacterizesimmunophenotypesingastrointestinalcancer |
| _version_ |
1718389891668115456 |